L

LTR Pharma Ltd
ASX:LTP

Watchlist Manager
LTR Pharma Ltd
ASX:LTP
Watchlist
Price: 0.74 AUD -2.63%
Market Cap: 113.8m AUD
Have any thoughts about
LTR Pharma Ltd?
Write Note

LTR Pharma Ltd
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LTR Pharma Ltd
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
L
LTR Pharma Ltd
ASX:LTP
Cash from Investing Activities
-AU$2k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Cash from Investing Activities
AU$53.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Cash from Investing Activities
-AU$163.3m
CAGR 3-Years
-2 633%
CAGR 5-Years
-571%
CAGR 10-Years
-136%
Botanix Pharmaceuticals Ltd
ASX:BOT
Cash from Investing Activities
-AU$18m
CAGR 3-Years
-1 195%
CAGR 5-Years
-323%
CAGR 10-Years
N/A
Probiotec Ltd
ASX:PBP
Cash from Investing Activities
-AU$14.4m
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Arovella Therapeutics Ltd
ASX:ALA
Cash from Investing Activities
-AU$179.3k
CAGR 3-Years
30%
CAGR 5-Years
34%
CAGR 10-Years
N/A
No Stocks Found

LTR Pharma Ltd
Glance View

Market Cap
103.2m AUD
Industry
Pharmaceuticals

LTR Pharma Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Brisbane, Queensland. The company went IPO on 2023-12-11. LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company. The firm is focused on holistically improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction (ED). Its lead product SPONTAN is set apart from existing ED therapies by its mechanism of action-intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work in 10 minutes or less. SPONTAN (SDS-089) is a novel intranasal drug (PDE5) delivery platform for Erectile Dysfunction.

LTP Intrinsic Value
0.01 AUD
Overvaluation 99%
Intrinsic Value
Price
L

See Also

What is LTR Pharma Ltd's Cash from Investing Activities?
Cash from Investing Activities
-2k AUD

Based on the financial report for Jun 30, 2024, LTR Pharma Ltd's Cash from Investing Activities amounts to -2k AUD.

What is LTR Pharma Ltd's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 1Y
1%

Over the last year, the Cash from Investing Activities growth was 1%.

Back to Top